FDA Continues To Clarify Antibiotic Requirements With New Guidance On Complicated UTI
A non-inferiority trial with a pre-specified non-inferiority margin is the most likely design for investigational antibacterial drugs targeted at cUTI, according to FDA draft guidance. Primary efficacy endpoint needs to include resolution of symptoms, on top of microbiological success.
You may also be interested in...
Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.
The agency checked another box on the list of guidances anticipated by developers of antibiotic drugs with the Oct. 1 release of a draft guidance on treatments for complicated intra-abdominal infections.
FDA public workshop will consider the design of clinical studies testing antibacterial drugs to treat lung damage caused by recurrent infections.